Risks for adverse events by sex and age after prescription opioid dose reduction
Recommended Citation
Metz VE, Palzes V, Binswanger IA, Altschuler A, Poulsen MN, Ahmedani BK, Andrade SE, Clark RE, Hechter RC, Horberg M, Sanchez K, Bailey SR, Stephens KA, Rubinstein AL, and Campbell CI. Risks for adverse events by sex and age after prescription opioid dose reduction. Am J Prev Med 2025;108085.
Document Type
Article
Publication Date
9-6-2025
Publication Title
American journal of preventive medicine
Abstract
INTRODUCTION: Prescription opioid dose reductions can raise the risk of adverse events for patients on long-term opioid therapy for non-cancer pain. Evidence on whether risks differ by age or sex is needed to support tailored clinical decision-making.
METHODS: In 2024, a secondary analysis of an observational cohort study was conducted across 8 U.S. healthcare systems analyzing electronic health record and claims data from a prescription opioid registry (excluding buprenorphine prescriptions) between 1/1/2012 and 12/31/2018, including adults with stable prescription opioid use and a subsequent ≥ 2-month dose reduction period (n=60,040), yielding 600,234 dose reduction periods as the analytic sample. Differences in the association between dose reduction level (1-< 15%, 15-< 30%, 30-< 100%, 100% from baseline) and potential adverse events (emergency department visits, opioid overdose, all-cause mortality, benzodiazepine prescription fills) in the month after dose reduction by sex and age group were examined by including interaction terms in logistic regression models.
RESULTS: Of the 600,234 dose reduction periods, 346,733 were among women, with a mean age of 57.5 [SD=13.2] years for women and 56.7 [SD=12.1] years for men. Associations between dose reduction levels and potential adverse events did not differ significantly by sex, but differed by age for emergency department visits: patients 40-64 and ≥ 65 years with dose reductions of 30-< 100% had lower odds compared to those aged 19-39 (adjusted ratio of odds ratios [aROR]=0.87, CI 0.80, 0.96; aROR=0.82, CI 0.74, 0.91; respectively).
CONCLUSIONS: Patients under 40 may benefit from closer monitoring in the month after dose reduction, given their higher odds of an emergency department visit.
PubMed ID
40921304
First Page
108085
Last Page
108085
